1
|
Tracy W, Davies GHM, Grant LN, Ganley JM, Moreno J, Cherney EC, Davies HML. Anhydrous and Stereoretentive Fluoride-Enhanced Suzuki-Miyaura Coupling of Immunomodulatory Imide Drug Derivatives. J Org Chem 2024; 89:4595-4606. [PMID: 38452367 PMCID: PMC11002932 DOI: 10.1021/acs.joc.3c02873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 02/12/2024] [Accepted: 02/17/2024] [Indexed: 03/09/2024]
Abstract
Immunomodulatory imide drugs form the core of many pharmaceutically relevant structures, but Csp2-Csp2 bond formation via metal-catalyzed cross coupling is difficult due to the sensitivity of the glutarimide ring ubiquitous in these structures. We report that replacement of the traditional alkali base with a fluoride source enhances a previously challenging Suzuki-Miyaura coupling on glutarimide-containing compounds with trifluoroborates. These enabling conditions are reactive enough to generate these derivatives in high yields but mild enough to preserve both the glutarimide and its sensitive stereocenter. Experimental and computational data suggest a mechanistically distinct process of π-coordination of the trifluoroborate enabled by these conditions.
Collapse
Affiliation(s)
- William
F. Tracy
- Department
of Chemistry, Emory University, Atlanta, Georgia 30322, United States
| | - Geraint H. M. Davies
- Small
Molecule Drug Discovery, Bristol Myers Squibb, Cambridge, Massachusetts 02140, United States
| | - Lauren N. Grant
- Chemical
Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
| | - Jacob M. Ganley
- Chemical
Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
| | - Jesus Moreno
- Small
Molecule Drug Discovery, Bristol Myers Squibb, San Diego, California 92121, United States
| | - Emily C. Cherney
- Small
Molecule Drug Discovery, Bristol Myers Squibb, Princeton, New Jersey 08543, United States
| | - Huw M. L. Davies
- Department
of Chemistry, Emory University, Atlanta, Georgia 30322, United States
| |
Collapse
|
2
|
Cherney EC, Zhang L, Lo J, Huynh T, Wei D, Ahuja V, Quesnelle C, Schieven GL, Futran A, Locke GA, Lin Z, Monereau L, Chaudhry C, Blum J, Li S, Fereshteh M, Li-Wang B, Gangwar S, Pan C, Chong C, Zhu X, Posy SL, Sack JS, Zhang P, Ruzanov M, Harner M, Akhtar F, Schroeder GM, Vite G, Fink B. Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization. J Med Chem 2022; 65:3518-3538. [PMID: 35108011 DOI: 10.1021/acs.jmedchem.1c01986] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The identification of agonists of the stimulator of interferon genes (STING) pathway has been an area of intense research due to their potential to enhance innate immune response and tumor immunogenicity in the context of immuno-oncology therapy. Initial efforts to identify STING agonists focused on the modification of 2',3'-cGAMP (1) (an endogenous STING activator ligand) and other closely related cyclic dinucleotides (CDNs). While these efforts have successfully identified novel CDNs that have progressed into the clinic, their utility is currently limited to patients with solid tumors that STING agonists can be delivered to intratumorally. Herein, we report the discovery of a unique class of non-nucleotide small-molecule STING agonists that demonstrate antitumor activity when dosed intratumorally in a syngeneic mouse model.
Collapse
Affiliation(s)
- Emily C Cherney
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Liping Zhang
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Julian Lo
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Tram Huynh
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Donna Wei
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Vijay Ahuja
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Claude Quesnelle
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Gary L Schieven
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Alan Futran
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Gregory A Locke
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Zeyu Lin
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Laura Monereau
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Charu Chaudhry
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jordan Blum
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Sha Li
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Mark Fereshteh
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Bifang Li-Wang
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Sanjeev Gangwar
- Bristol Myers Squibb Research and Development, 700 Bay Rd, Redwood City, California 94063, United States
| | - Chin Pan
- Bristol Myers Squibb Research and Development, 700 Bay Rd, Redwood City, California 94063, United States
| | - Colin Chong
- Bristol Myers Squibb Research and Development, 700 Bay Rd, Redwood City, California 94063, United States
| | - Xiao Zhu
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Shana L Posy
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - John S Sack
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Ping Zhang
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Max Ruzanov
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Mary Harner
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Fahad Akhtar
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Gretchen M Schroeder
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Gregory Vite
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Brian Fink
- Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
3
|
Liu S, Zhuang Z, Qiao JX, Yeung KS, Su S, Cherney EC, Ruan Z, Ewing WR, Poss MA, Yu JQ. Ligand Enabled Pd(II)-Catalyzed γ-C(sp 3)-H Lactamization of Native Amides. J Am Chem Soc 2021; 143:21657-21666. [PMID: 34914877 PMCID: PMC9116424 DOI: 10.1021/jacs.1c10183] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
γ-Lactams form important structural cores of a range of medicinally relevant natural products and clinical drugs, principal examples being the new generation of immunomodulatory imide drugs (IMiDs) and the brivaracetam family. Compared to conventional multistep synthesis, an intramolecular γ-C-H amination of aliphatic amides would allow for the direct construction of valuable γ-lactam motifs from abundant amino acid precursors. Herein we report a novel 2-pyridone ligand enabled Pd(II)-catalyzed γ-C(sp3)-H lactamization of amino acid derived native amides, providing the convenient synthesis of γ-lactams, isoindolinones, and 2-imidazolidinones. C6-Substitution of the 2-pyridone ligand is crucial for the lactam formation. This protocol features the use of N-acyl amino acids, which serve as both the directing group and cyclization partner, practical and environmentally benign tert-butyl hydrogen peroxide (TBHP) as the sole bystanding oxidant, and a broad substrate scope. The utility of this protocol was demonstrated through the two-step syntheses of a lenalidomide analog and brivaracetam from readily available carboxylic acids and amino acids.
Collapse
Affiliation(s)
- Shuang Liu
- Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States
| | - Zhe Zhuang
- Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States
| | - Jennifer X. Qiao
- Discovery Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kap-Sun Yeung
- Bristol Myers Squibb Research and Development, 100 Binney Street, Cambridge, MA 02142, United States
| | - Shun Su
- Bristol Myers Squibb, 10300 Campus Point Drive Suite 100, San Diego, CA 92121, United States
| | - Emily C. Cherney
- Discovery Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Zheming Ruan
- Discovery Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - William R. Ewing
- Discovery Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Michael A. Poss
- Discovery Chemistry, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jin-Quan Yu
- Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, United States,Corresponding Author.
| |
Collapse
|
4
|
Nimje RY, Kuppusamy P, Krishnamoorthy S, Shanmugam Y, Ramasamy D, Manoharan H, Arunachalam PN, Balog A, Cherney EC, Zhang L, Borzilleri RM, Hong Z, Kempson J, Rampulla RR, Mathur A, Gupta A. Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-(( R)-1-(( cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00142] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Roshan Y. Nimje
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Prakasam Kuppusamy
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Suresh Krishnamoorthy
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Yoganand Shanmugam
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Duraisamy Ramasamy
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Haridhas Manoharan
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Pirama Nayagam Arunachalam
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Aaron Balog
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Emily C. Cherney
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Liping Zhang
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Robert M. Borzilleri
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Zhenqiu Hong
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - James Kempson
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Richard R. Rampulla
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Arvind Mathur
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Anuradha Gupta
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Limited, Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| |
Collapse
|
5
|
Cherney EC, Zhang L, Guo W, Huang A, Williams D, Seitz S, Shan W, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, D’Arienzo CJ, Discenza LN, Ranasinghe A, Grubb MF, Traeger SC, Li X, Johnston KA, Kopcho L, Fereshteh M, Foster KA, Stefanski K, Delpy D, Dhar G, Anandam A, Mahankali S, Padmanabhan S, Rajanna P, Murali V, Mariappan TT, Pattasseri S, Nimje RY, Hong Z, Kempson J, Rampulla R, Mathur A, Gupta A, Borzilleri R, Vite G, Balog A. Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors. ACS Med Chem Lett 2021; 12:1143-1150. [PMID: 34267885 DOI: 10.1021/acsmedchemlett.1c00236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 06/11/2021] [Indexed: 12/21/2022] Open
Abstract
IDO1 inhibitors have shown promise as immunotherapies for the treatment of a variety of cancers, including metastatic melanoma and renal cell carcinoma. We recently reported the identification of several novel heme-displacing IDO1 inhibitors, including the clinical molecules linrodostat (BMS-986205) and BMS-986242. Both molecules contain quinolines that, while being present in successful medicines, are known to be potentially susceptible to oxidative metabolism. Efforts to swap this quinoline with an alternative aromatic system led to the discovery of 2,3-disubstituted pyridines as suitable replacements. Further optimization, which included lowering ClogP in combination with strategic fluorine incorporation, led to the discovery of compound 29, a potent, selective IDO1 inhibitor with robust pharmacodynamic activity in a mouse xenograft model.
Collapse
Affiliation(s)
- Emily C. Cherney
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Liping Zhang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Weiwei Guo
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Audris Huang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - David Williams
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Steven Seitz
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Weifang Shan
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Xiao Zhu
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Johnni Gullo-Brown
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Derrick Maley
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Tai-an Lin
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - John T. Hunt
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Christine Huang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Zheng Yang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Celia J. D’Arienzo
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Lorell N. Discenza
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Asoka Ranasinghe
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Mary F. Grubb
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Sarah C. Traeger
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Xin Li
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Kathy A. Johnston
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Lisa Kopcho
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Mark Fereshteh
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Kimberly A. Foster
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Kevin Stefanski
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Diane Delpy
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Gopal Dhar
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Aravind Anandam
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Sandeep Mahankali
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Shweta Padmanabhan
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Prabhakar Rajanna
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Venkata Murali
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - T. Thanga Mariappan
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Shabeerali Pattasseri
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Roshan Y. Nimje
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Zhenqiu Hong
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - James Kempson
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Richard Rampulla
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Arvind Mathur
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Anuradha Gupta
- Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India
| | - Robert Borzilleri
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Gregory Vite
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| | - Aaron Balog
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Road, Lawrence Township, New Jersey 08648, United States
| |
Collapse
|
6
|
Zhang L, Cherney EC, Zhu X, Lin TA, Gullo-Brown J, Maley D, Johnston-Allegretto K, Kopcho L, Fereshteh M, Huang C, Li X, Traeger SC, Dhar G, Anandam A, Mahankali S, Padmanabhan S, Rajanna P, Murali V, Mariappan T, Borzilleri R, Vite G, Hunt JT, Balog A. Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy. ACS Med Chem Lett 2021; 12:494-501. [PMID: 33738077 DOI: 10.1021/acsmedchemlett.1c00014] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 02/26/2021] [Indexed: 11/30/2022] Open
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-molecule immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma. This work focuses on the identification of IDO1 inhibitors containing replacements or isosteres for the amide found in BMS-986205, an amide-containing, IDO1-selective inhibitor currently in phase III clinical trials. Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-containing IDO1 inhibitors.
Collapse
Affiliation(s)
- Liping Zhang
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Emily C. Cherney
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Xiao Zhu
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Tai-an Lin
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Johnni Gullo-Brown
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Derrick Maley
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | | | - Lisa Kopcho
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Mark Fereshteh
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Christine Huang
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Xin Li
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Sarah C. Traeger
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Gopal Dhar
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Aravind Anandam
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Sandeep Mahankali
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Shweta Padmanabhan
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Prabhakar Rajanna
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Venkata Murali
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Thanga Mariappan
- Biocon Bristol Myers Squibb R&D Center, Biocon Park, Jigani Link Road, Bengaluru, Karnataka 560099, India
| | - Robert Borzilleri
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Gregory Vite
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - John T. Hunt
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Aaron Balog
- Bristol Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
7
|
Cherney EC, Zhang L, Nara S, Zhu X, Gullo-Brown J, Maley D, Lin TA, Hunt JT, Huang C, Yang Z, Darienzo C, Discenza L, Ranasinghe A, Grubb M, Ziemba T, Traeger SC, Li X, Johnston K, Kopcho L, Fereshteh M, Foster K, Stefanski K, Fargnoli J, Swanson J, Brown J, Delpy D, Seitz SP, Borzilleri R, Vite G, Balog A. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. ACS Med Chem Lett 2021; 12:288-294. [PMID: 33603977 DOI: 10.1021/acsmedchemlett.0c00668] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 01/22/2021] [Indexed: 01/14/2023] Open
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing dioxygenase enzyme implicated in cancer immune response. This account details the discovery of BMS-986242, a novel IDO1 inhibitor designed for the treatment of a variety of cancers including metastatic melanoma and renal cell carcinoma. Given the substantial interest around this target for cancer immunotherapy, we sought to identify a structurally differentiated clinical candidate that performs comparably to linrodostat (BMS-986205) in terms of both in vitro potency and in vivo pharmacodynamic effect in a mouse xenograft model. On the basis of its preclinical profile, BMS-986242 was selected as a candidate for clinical development.
Collapse
Affiliation(s)
- Emily C. Cherney
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Liping Zhang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Susheel Nara
- Biocon BMS R&D Center, Bommasandra Jigani Link Rd, Bommasandra Industrial Area, Bengaluru, Karnataka 560099, India
| | - Xiao Zhu
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Johnni Gullo-Brown
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Derrick Maley
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Tai-An Lin
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - John T. Hunt
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Christine Huang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Zheng Yang
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Celia Darienzo
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Lorell Discenza
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Asoka Ranasinghe
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Mary Grubb
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Theresa Ziemba
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Sarah C. Traeger
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Xin Li
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Kathy Johnston
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Lisa Kopcho
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Mark Fereshteh
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Kimberly Foster
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Kevin Stefanski
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Joseph Fargnoli
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Jesse Swanson
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Jennifer Brown
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Diane Delpy
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Steven P. Seitz
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Robert Borzilleri
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Gregory Vite
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| | - Aaron Balog
- Bristol Myers Squibb Research and Development, 3551 Lawrenceville, Princeton Rd, Lawrence Township, New Jersey 08648, United States
| |
Collapse
|
8
|
Vasquez AM, Gurak JA, Joe CL, Cherney EC, Engle KM. Catalytic α-Hydroarylation of Acrylates and Acrylamides via an Interrupted Hydrodehalogenation Reaction. J Am Chem Soc 2020; 142:10477-10484. [PMID: 32379433 PMCID: PMC7293711 DOI: 10.1021/jacs.0c03040] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The palladium-catalyzed, α-selective hydroarylation of acrylates and acrylamides is reported. Under optimized conditions, this method is highly tolerant of a wide range of substrates including those with base sensitive functional groups and/or multiple enolizable carbonyl groups. A detailed mechanistic study was undertaken, and the high selectivity of this transformation was shown to be enabled by the formation of a [PdII(Ar)(H)] intermediate, which performs selective hydride insertion into the β-position of α,β-unsaturated carbonyl compounds.
Collapse
Affiliation(s)
- Alena M. Vasquez
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - John A. Gurak
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Candice L. Joe
- Chemistry Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States
| | - Emily C. Cherney
- Discovery Chemistry, Bristol Myers Squibb, US Rt. 206 & Province Line Road, Princeton, New Jersey 08540, United States
| | - Keary M. Engle
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
9
|
Cherney EC, Green JC, Baran PS. Synthesis ofent-Kaurane and Beyerane Diterpenoids by Controlled Fragmentations of Overbred Intermediates. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201304609] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
10
|
Cherney EC, Green JC, Baran PS. Synthesis of ent-kaurane and beyerane diterpenoids by controlled fragmentations of overbred intermediates. Angew Chem Int Ed Engl 2013; 52:9019-22. [PMID: 23861294 DOI: 10.1002/anie.201304609] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2013] [Revised: 06/20/2013] [Indexed: 11/09/2022]
Affiliation(s)
- Emily C Cherney
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
11
|
Abstract
Terpenes and alkaloids are ever-growing classes of natural products that provide new molecular structures which inspire chemists and possess a broad range of biological activity. Terpenoid-alkaloids originate from the same prenyl units that construct terpene skeletons. However, during biosynthesis, a nitrogen atom (or atoms) is introduced in the form of β-aminoethanol, ethylamine, or methylamine. Nitrogen incorporation can occur either before, during, or after the cyclase phase. The outcome of this unique biosynthesis is the formation of natural products containing unprecedented structures. These complex structural motifs expose current limitations in organic chemistry, thus providing opportunities for invention. This review focuses on total syntheses of terpenoid-alkaloids and unique issues presented by this class of natural products. More specifically, it examines how these syntheses relate to the way terpenoid-alkaloids are made in Nature. Developments in chemistry that have facilitated these syntheses are emphasized, as well as chemical technology needed to conquer those that evade synthesis.
Collapse
Affiliation(s)
- Emily C. Cherney
- Department of Chemistry, The Scripps Research Institute 10550 N. Torrey Pines Rd, La Jolla, CA 92037 phone: (+1) 858-784-7370 fax: (+1) 858-784-7375
| | - Phil S. Baran
- Department of Chemistry, The Scripps Research Institute 10550 N. Torrey Pines Rd, La Jolla, CA 92037 phone: (+1) 858-784-7370 fax: (+1) 858-784-7375
| |
Collapse
|
12
|
Castro S, Cherney EC, Snyder NL, Peczuh MW. Synthesis of substituted septanosyl-1,2,3-triazoles. Carbohydr Res 2007; 342:1366-72. [PMID: 17466290 DOI: 10.1016/j.carres.2007.03.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2007] [Revised: 03/22/2007] [Accepted: 03/26/2007] [Indexed: 01/27/2023]
Abstract
A carbohydrate-based oxepine, derived from 2-deoxy-D-arabino-hexopyranose, was used to prepare a family of septanosyl-1,2,3-triazoles in four steps. DMDO mediated epoxidation of the oxepine followed by trapping of the intermediate 1,2-anhydroseptanose by sodium azide gave the beta-substituted glycosyl azide. The septanosyl azide was then reacted with a number of alkynes under thermal Huisgen or copper(I) mediated reaction conditions. Hydrogenolysis of benzyl protecting groups gave substituted septanosyl-1,2,3-triazoles. The new septanose-based structures were then evaluated as potential glycosidase inhibitors.
Collapse
Affiliation(s)
- Steve Castro
- Department of Chemistry, University of Connecticut, U-3060, 55 North Eagleville Road, Storrs, CT 06269, United States
| | | | | | | |
Collapse
|